4.5 Review

Defining cancer risk in dermatomyositis. Part I

Journal

CLINICAL AND EXPERIMENTAL DERMATOLOGY
Volume 34, Issue 4, Pages 451-455

Publisher

WILEY
DOI: 10.1111/j.1365-2230.2009.03216.x

Keywords

-

Categories

Funding

  1. Arthritis Research Campaign [16082]
  2. National Institute for Health Research [CL-2006-06-010] Funding Source: researchfish

Ask authors/readers for more resources

The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion-body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle-specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. Clinical, serological and histological criteria can be used to define individual IIM subtypes. In the first of this two-part review series, we examine the evidence for the existence of cancer-associated myositis (CAM), and in part 2, we discuss recent discoveries that provide insight into identification of patients with DM, who may be most at risk of developing CAM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available